Outcomes with Biological Disease-Modifying Anti-Rheumatic Drugs (bDMARDs) in Older Patients Treated for Rheumatoid Arthritis

BACKGROUND: Biological disease-modifying antirheumatic drugs (bDMARDs) are recommended for rheumatoid arthritis (RA), but older patients reportedly experience more adverse events (AEs) and show variable treatment response. The objective of this study was to evaluate AEs and effectiveness of bDMARDs...

Полное описание

Библиографические подробности
Главные авторы: Akter, Ripa, Maksymowych, Walter P., Martin, M. Liam, Hogan, David B.
Формат: Online Статья Текст
Язык:English
Опубликовано: Canadian Geriatrics Society 2020
Предметы:
Original Research
Online-ссылка:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7259924/
https://www.ncbi.nlm.nih.gov/pubmed/32494334
http://dx.doi.org/10.5770/cgj.23.393

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7259924/
https://www.ncbi.nlm.nih.gov/pubmed/32494334
http://dx.doi.org/10.5770/cgj.23.393

Схожие документы